United-Guardian, Inc. — 2015 Form 10-K
Reporting period: Fiscal year ended December 31, 2015. The filing is an annual report; the supplied text does not provide standalone fourth-quarter financial results.
Business context
United-Guardian manufactures and markets personal care and cosmetic ingredients, pharmaceuticals, medical lubricants, and specialty industrial products. It operates as one business segment. LUBRAJEL products generated 85.3% of 2015 revenue and RENACIDIN generated 9.6%, together accounting for 94.9% of revenue. Sales rely substantially on marketing partners and distributors.
Financial performance
| Metric | 2015 | 2014 | Change |
|---|---|---|---|
| Net sales | $14.01 million | $13.45 million | +4.1% |
| Income from operations | $6.29 million | $5.49 million | +14.6% |
| Net income | $4.61 million | $4.05 million | +13.7% |
| Diluted earnings per share | $1.00 | $0.88 | +$0.12 |
| Operating margin | 44.9% | 40.8% | +4.1 percentage points |
| Net margin | 32.9% | 30.1% | +2.8 percentage points |
| Cash from operations | $5.20 million | $4.48 million | +16.1% |
Cost of sales declined to 37.1% of sales from 39.5%, which management attributed to higher production efficiency and a more favorable product mix. R&D expense was $648,211, down 11.3%. The effective tax rate was 30.4%, versus 29.6%.
At year-end, cash and cash equivalents were $1.08 million and marketable securities were $10.72 million. Working capital was $13.53 million, with a 14.7:1 current ratio. Total assets were $15.69 million and stockholders’ equity was $14.58 million. The balance sheet reports no borrowings; management said it had no line of credit and no foreseeable need for one. The company paid $4.59 million in dividends during 2015 and declared total dividends of $1.00 per share.
Investing activities used $1.67 million, mainly reflecting purchases of marketable securities. Financing activities used $4.47 million, primarily dividends. Cash declined by $943,000 over the year. The company reported no material capital expenditure commitments or off-balance-sheet arrangements.
Material changes and outlook
- Personal care sales rose 5.3%, principally on increased sales to ASI for China. Medical product sales fell 11.6%, which management attributed mainly to customer ordering patterns. Pharmaceutical sales increased 10.5%, with most of the increase from RENACIDIN.
- China-related sales to ASI slowed sharply in the fourth quarter because of an unrelated regulatory issue affecting customers’ products and excess inventory in China. Based on ASI’s information, management expected sales to China to resume in the third quarter of 2016, with a significant effect on first-half 2016 sales.
- RENACIDIN received FDA approval in December 2015 for a new single-dose 30 mL package. The company expected to begin selling it in April 2016 and anticipated potential sales growth, but provided no quantified forecast. Existing 500 mL inventory was expected to sell down around the transition.
- Management expected 2016 R&D expense to be comparable to 2015. It hoped to begin marketing two additional natural LUBRAJEL products by year-end 2016; development and commercialization were not assured.
- Management cited lower-priced imitations, pricing pressure, a strong U.S. dollar, and weak European conditions as competitive risks that could reduce sales or margins. Two distributors/marketing partners represented 65.9% of revenue in 2015; one customer alone accounted for $8.46 million, about 60% of sales. Five suppliers represented 89% of raw-material purchases.
- Other notable items: ASI owed an $88,360 rebate repayment after a customer failed to meet purchase commitments; the final $24,402 RENACIDIN supplier settlement payment was received in 2014, with none in 2015. Marketable securities had $284,103 in gross unrealized losses during 2015; management considered declines below cost temporary and recorded no impairment.
Risks, contingencies, and controls
The filing identifies exposure to distributor and customer concentration, competition and imitation products, foreign-market price competitiveness, customer order variability, regulatory approvals, and the company’s ability to develop and commercialize products. Other risks include customer credit and inventory obsolescence. No legal proceedings were reported. Management concluded disclosure controls and internal control over financial reporting were effective; the independent auditor did not provide an internal-control attestation.
Key facts for investors to verify
- Whether China-related orders resumed as expected in the third quarter of 2016 and how the interruption affected 2016 revenue.
- RENACIDIN launch timing, customer adoption, and sales recovery after the packaging and supplier transition.
- Whether pricing pressure from lower-cost competitors is affecting LUBRAJEL volume, discounts, and gross margins.
- The durability of distributor and customer relationships, particularly the concentrated ASI channel and major-customer exposure.
- Marketable-security values, dividend sustainability, and the company’s ability to maintain operating cash flow as sales and product mix change.